• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Neurol . Neurologic symptoms as a hallmark of glymphatic alteration in recovered patients with COVID-19

tetano

Editor, Senior Moderator
BMC Neurol


. 2025 Apr 28;25(1):187.
doi: 10.1186/s12883-025-04198-1. Neurologic symptoms as a hallmark of glymphatic alteration in recovered patients with COVID-19

Minhoe Kim[SUP] #[/SUP][SUP] 1 [/SUP], Kyung Hoon Lee[SUP] #[/SUP][SUP] 2 [/SUP], Ji Su Ko[SUP] 2 [/SUP], Myung Sub Kim[SUP] 2 [/SUP], Kyu Sung Choi[SUP] 3 [/SUP], Jiwon Seo[SUP] 4 [/SUP], Minchul Kim[SUP] 5 [/SUP]



Affiliations
Abstract

Background: The glymphatic system is a glial-based perivascular network that facilitates the clearance of metabolic waste from the brain. Dysfunction of the glymphatic system, along with neurological symptoms such as cognitive deficits and olfactory dysfunction, has been reported in patients with coronavirus disease (COVID-19). However, the link between these neurological symptoms and alterations in the glymphatic system remains unclear. In this study, we aimed to evaluate magnetic resonance imaging (MRI)-based measures of the glymphatic system in patients recovered from COVID-19 with and without neurological symptoms.
Methods: This study included 89 patients who recovered from respiratory infections, of whom 71 had confirmed COVID-19 (20 experienced anosmia and 41 had cognitive symptoms). Three MRI-based measures were quantified and compared: the dilated perivascular spaces (dPVS), free water (FW) fraction, and diffusion tensor image analysis along the perivascular spaces (DTI-ALPS). A partial correlation network was used to assess the relationships between COVID-19 infection, neurological symptoms, and glymphatic measures.
Results: COVID-19 patients with anosmia had increased FW in the left orbitofrontal area compared to those without anosmia (mean difference: 0.01, p = 0.48), while patients with cognitive symptoms showed decreased left-sided DTI-ALPS (mean difference: 0.06, p = 0.40). Neurological symptoms mediate the relationship between COVID-19 and glymphatic system measures.
Conclusions: Our findings imply that neurological symptoms accompanied by COVID-19 are linked to distinct alterations in the glymphatic system, suggesting a potential association between neuroinvasion and neuroinflammatory processes related to COVID-19.

Keywords: Anosmia; COVID-19; DTI-ALPS; Glymphatic alteration.

 
Back
Top Bottom